Corporate Highlights

• Formed in 2002, founded by 3 ORNL scientists, based in Knoxville, TN, OTCBB: PVCT

• Engaged in the development of PV-10 (Rose Bengal) as a novel chemotherapeutic agent for cancer and skin disorders.

• Deep Patent Portfolio, 23US, 29Foreign Issued Patents (6 Technology Areas, 5 non-core subsidiaries to be spun-off)

• Both oncology and dermatology markets are multi-billion markets with clear un-met medical needs

• Clinical Progress- Valuation Inflection Point

• • Oncology: Melanoma Phase 2, Breast 1, Liver 1/2
  • Dermatology: Psoriasis Phase 2, Eczema Phase 2